Algorae Pharmaceuticals Ltd
Company Profile
Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUST: +61 422180317
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
35
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,853.70 | 60.20 | -0.76% |
| CAC 40 | 7,104.80 | 21.22 | -0.30% |
| DAX 40 | 20,374.10 | 188.63 | -0.92% |
| Dow JONES (US) | 40,212.71 | 619.05 | 1.56% |
| FTSE 100 | 7,964.18 | 50.93 | 0.64% |
| HKSE | 20,914.69 | 232.91 | 1.13% |
| NASDAQ | 16,724.46 | 337.14 | 2.06% |
| Nikkei 225 | 33,585.58 | 1,023.42 | -2.96% |
| NZX 50 Index | 12,019.13 | 182.30 | -1.49% |
| S&P 500 | 5,363.36 | 95.31 | 1.81% |
| S&P/ASX 200 | 7,646.50 | 63.10 | -0.82% |
| SSE Composite Index | 3,238.23 | 14.59 | 0.45% |